Corbus Pharmaceuticals (CRBP) Expected to Announce Quarterly Earnings on Tuesday

Corbus Pharmaceuticals (NASDAQ:CRBP) is projected to issue its Q1 2026 results before the market opens on Tuesday, May 5th. Analysts expect the company to announce earnings of ($1.26) per share for the quarter. Parties can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Friday, May 15, 2026 at 12:30 PM ET.

Corbus Pharmaceuticals (NASDAQ:CRBP) last issued its earnings results on Monday, March 9th. The biopharmaceutical company reported ($1.25) EPS for the quarter, topping the consensus estimate of ($1.78) by $0.53. On average, analysts expect Corbus Pharmaceuticals to post $-5 EPS for the current fiscal year and $-6 EPS for the next fiscal year.

Corbus Pharmaceuticals Price Performance

Shares of NASDAQ CRBP opened at $10.30 on Monday. Corbus Pharmaceuticals has a 52 week low of $6.10 and a 52 week high of $20.56. The firm’s fifty day moving average is $9.32 and its 200 day moving average is $10.02. The company has a market cap of $182.72 million, a price-to-earnings ratio of -1.72 and a beta of 2.68.

Insider Activity at Corbus Pharmaceuticals

In other Corbus Pharmaceuticals news, insider Dominic Smethurst sold 3,285 shares of Corbus Pharmaceuticals stock in a transaction on Tuesday, February 3rd. The stock was sold at an average price of $8.09, for a total value of $26,575.65. Following the completion of the sale, the insider owned 95,887 shares of the company’s stock, valued at approximately $775,725.83. This trade represents a 3.31% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 3.50% of the company’s stock.

Institutional Trading of Corbus Pharmaceuticals

Several large investors have recently modified their holdings of the company. Orbimed Advisors LLC grew its holdings in shares of Corbus Pharmaceuticals by 36.3% in the fourth quarter. Orbimed Advisors LLC now owns 1,597,287 shares of the biopharmaceutical company’s stock worth $13,002,000 after acquiring an additional 425,000 shares during the period. Prosight Management LP lifted its position in shares of Corbus Pharmaceuticals by 99.1% in the fourth quarter. Prosight Management LP now owns 683,872 shares of the biopharmaceutical company’s stock valued at $5,567,000 after acquiring an additional 340,472 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Corbus Pharmaceuticals by 2.1% in the third quarter. Vanguard Group Inc. now owns 612,030 shares of the biopharmaceutical company’s stock valued at $7,742,000 after acquiring an additional 12,535 shares in the last quarter. Armistice Capital LLC lifted its position in shares of Corbus Pharmaceuticals by 179.2% in the fourth quarter. Armistice Capital LLC now owns 536,000 shares of the biopharmaceutical company’s stock valued at $4,363,000 after acquiring an additional 344,000 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its position in shares of Corbus Pharmaceuticals by 230.5% in the fourth quarter. Renaissance Technologies LLC now owns 354,300 shares of the biopharmaceutical company’s stock valued at $2,884,000 after acquiring an additional 247,100 shares in the last quarter. Institutional investors own 64.64% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on CRBP. Oppenheimer lifted their price objective on Corbus Pharmaceuticals from $53.00 to $57.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 10th. Wall Street Zen upgraded Corbus Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Saturday, April 25th. Guggenheim assumed coverage on Corbus Pharmaceuticals in a research report on Wednesday. They issued a “buy” rating and a $45.00 price objective on the stock. Jefferies Financial Group upgraded Corbus Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, February 18th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Corbus Pharmaceuticals in a research note on Monday, April 20th. Two research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, Corbus Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $43.88.

Corbus Pharmaceuticals Company Profile

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of therapeutic candidates for rare, life-threatening inflammatory and fibrotic diseases. The company’s lead investigational therapy, lenabasum, is a synthetic, oral cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation by harnessing the body’s innate resolution pathways. Corbus operates by advancing small-molecule compounds through preclinical and clinical studies to address unmet medical needs in autoimmune and inflammatory disorders.

Lenabasum is currently under evaluation in a Phase 3 clinical trial for diffuse cutaneous systemic sclerosis (dcSSc) and in a Phase 2 study for cystic fibrosis–related inflammation.